Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
82
1

Year Published

2009
2009
2016
2016

Publication Types

Select...
5
4
1

Relationship

0
10

Authors

Journals

citations
Cited by 122 publications
(86 citation statements)
references
References 53 publications
3
82
1
Order By: Relevance
“…52) EP 1 receptors are not only expressed in the primary afferents, but also in the urothelium, contributing to PGE 2 -induced facilitation of the micturition reflex and to enhanced afferent nerve activity during urinary bladder inflammation. 53,54) We have shown that ONO-8130, a selective EP 1 receptor antagonist, reverses bladder pain-like behavior and referred hyperalgesia in mice with cyclophosphamide-induced cystitis, and prevents prompt phosphorylation of ERK in the spinal dorsal horn following intravesical administration of PGE 2 .…”
Section: Application Of Pge 2 Receptor Antago-nists To Treatment Of Vmentioning
confidence: 98%
“…52) EP 1 receptors are not only expressed in the primary afferents, but also in the urothelium, contributing to PGE 2 -induced facilitation of the micturition reflex and to enhanced afferent nerve activity during urinary bladder inflammation. 53,54) We have shown that ONO-8130, a selective EP 1 receptor antagonist, reverses bladder pain-like behavior and referred hyperalgesia in mice with cyclophosphamide-induced cystitis, and prevents prompt phosphorylation of ERK in the spinal dorsal horn following intravesical administration of PGE 2 .…”
Section: Application Of Pge 2 Receptor Antago-nists To Treatment Of Vmentioning
confidence: 98%
“…11,12 Systemic administration of EP1 antagonist attenuates esophageal hyperalgesia in human and bladder pain in cystitis model mice. 7,13 Regarding EP1 receptor and bladder function, it is suggested that intravesical PGE2 promotes micturition reflex by stimulating C-fiber afferent nerves via EP1 receptor. 14,15 These previous studies and the present study indicate that the action of PGE2 via EP1 receptor has an important role in the development of bladder pain and urinary frequency in ulcer-type IC/BPS.…”
mentioning
confidence: 99%
“…At present, there have been few reported clinical studies using EP antagonists (35,36) and no specific inhibitor for TMPRSS4 has yet been developed. If a potent, specific, and safe way to attack these targets is exploited, it may provide a promising therapeutic strategy for the repression of ovarian cancer metastasis by combining existing agents for ovarian cancer therapy.…”
Section: Discussionmentioning
confidence: 99%